



VIA HAND DELIVERY MARCH 14, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Moore et al.

Attorney Docket No.: PZ032P1C3

Serial No.: 10/054,988

Group Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

Title: **49 Human Secreted Proteins**

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to document AW, a Supplemental Partial European Search Report, mailed February 15, 2002, listed on the attached Form PTO/SB/08. A copy of document AW is enclosed.

The listed document is directed to a gene that is different from the one being pursued in this application. Nevertheless, under 37 C.F.R. § 1.56, Applicant's wish to draw the Examiner's attention to this document. At the Examiner's request, a copy of the references cited in the Supplementary Partial European Search Report can be provided.

Accordingly, the undersigned certifies, pursuant to 37 C.F.R. § 1.97(e)(1), that this item of information was forwarded in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement.


The listed reference is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed reference of record in the file

history of the application and consider the information contained therein during the prosecution of this application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.


Respectfully submitted,

Date: March 14, 2002


Janet M. Martineau Reg. No. 46,903
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Phone: (301) 315-2723

JMM/ CEW/mm



Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**